RecruitingPhase 3NCT06449677
Bionic Pancreas in CFRD
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jaeb Center for Health Research
- Principal Investigator
- Melissa Putman, MDMassachusetts General Hospital
- Intervention
- iLet Bionic Pancreas System (BP)(device)
- Enrollment
- 150 target
- Eligibility
- 14 years · All sexes
- Timeline
- 2024 – 2027
Study locations (16)
- University of Colorado-Barbara Davis Center for Diabetes, Aurora, Colorado, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Emory University, Atlanta, Georgia, United States
- Indiana University School of Medicine, Indianapolis, Indiana, United States
- Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Children's Mercy Hospital, Kansas City, Missouri, United States
- Columbia University Medical Center, New York, New York, United States
- University Hospitals of Cleveland, Cleveland, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- Baylor College of Medicine, Houston, Texas, United States
- University of Texas Health San Antonio, San Antonio, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
- +1 more locations on ClinicalTrials.gov
Collaborators
Cystic Fibrosis Foundation · Massachusetts General Hospital · Beta Bionics, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06449677 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS